CRESCENT BIOPHARMA, INC.(CBIO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

CRESCENT BIOPHARMA, INC. (CBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CBIO at 9.6/100 on a 32-signal composite quality model, placing it at rank #2,916 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (0.4) and free cash flow (0.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CRESCENT BIOPHARMA, INC. reports net income of $-24.8M, free cash flow of $-19.5M. Top institutional holders of CBIO by reported 13-F value include FMR, BVF, Fairmount Funds Management, based on the most recent SEC filings. CBIO trades on the Nasdaq exchange and files with the SEC under CIK 1253689. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CRESCENT BIOPHARMA, INC. directly from SEC EDGAR.